See more : I-Tech AB (ITECH.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Opthea Limited (OPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Opthea Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jowell Global Ltd. (JWEL) Income Statement Analysis – Financial Results
- Beijing Tieke Shougang Rail Way-Tech Co., Ltd. (688569.SS) Income Statement Analysis – Financial Results
- Li Auto Inc. (2015.HK) Income Statement Analysis – Financial Results
- PT Karya Bersama Anugerah Tbk (KBAG.JK) Income Statement Analysis – Financial Results
- Tianjin Binhai Energy & Development Co.,Ltd (000695.SZ) Income Statement Analysis – Financial Results
Opthea Limited (OPT)
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | 0.00 | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 250.47K | 232.47K | 571.98K | 517.26K | 273.94K | 28.66K | 26.61K | 30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | -161.45K | -28.66K | -26.61K | -30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | -27.35K | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% | -143.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 176.33M | 181.56M | 108.46M | 34.71M | 17.48M | 31.35M | 24.89M | 4.84M | 3.58M | 4.28M | 3.40M | 3.14M | 3.68M | 7.02M | 3.65M | 3.62M | 3.27M | 2.67M | 1.20M | 533.75K | 349.78K | 106.50K | 144.69K | 553.00K | 186.15K | 358.33K | 600.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.67K | 0.00 | 0.00 |
| General & Administrative | 15.49M | 19.27M | 16.30M | 11.88M | 6.61M | 5.09M | 2.70M | 3.25M | 2.86M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 22.63M | 8.52M | 6.54M | 43.14K | 108.90K | 2.29M | 629.16K | 613.02K | 359.30K | 477.17K | 538.63K | 467.15K | 713.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.49M | 41.90M | 24.83M | 18.42M | 6.65M | 5.20M | 4.99M | 5.03M | 4.47M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Other Expenses | 152.46K | 12.30M | 0.00 | 0.00 | 0.00 | 56.76K | 2.03K | 1.23K | 6.23K | 48.00K | 183.04K | 29.55K | 199.06K | 78.32K | 2.12K | 106.79K | 5.76K | 130.52K | 50.38K | 22.90M | 5.33M | 11.79K | 96.84K | 875.00K | 1.59M | 2.79M | 73.54K | 81.79K | 11.03K | 47.58K | 432.57K | 9.00K | 10.00K | 20.00K | 10.00K | 4.53K |
| Operating Expenses | 191.97M | 223.46M | 133.29M | 53.13M | 24.71M | 36.27M | 29.88M | 9.87M | 8.05M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 520.09K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Cost & Expenses | 191.97M | 223.61M | 133.40M | 53.27M | 25.23M | 36.54M | 29.91M | 9.90M | 8.08M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 547.44K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Interest Income | 3.39M | 4.80M | 324.70K | 498.70K | 696.18K | 755.78K | 735.70K | 384.35K | 325.57K | 324.56K | 258.85K | 530.99K | 998.39K | 1.48M | 1.39M | 1.86M | 3.12M | 1.73M | 815.55K | 1.14M | 617.15K | 569.19K | 579.33K | 1.59M | 326.53K | 106.45K | 72.52K | 158.75K | 82.69K | 54.69K | 36.54K | 7.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.26M | 20.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.11K | 0.00 | 391.82K | 0.00 | 0.00 | 71.87K | 179.45K | 0.00 | 0.00 | 1.13K | 8.16K | 0.00 | 0.00 | 1.98M | 1.40M | 787.50 | 1.42K | 1.46K | 668.00 | 2.24K | 5.37K | 3.97K | 7.55K | |
| Depreciation & Amortization | 103.03K | 150.49K | 108.08K | 143.00K | 144.02K | 33.09K | 28.66K | 26.61K | 30.79K | 29.58K | 35.98K | 24.95K | 29.25K | 30.02K | 24.30K | 27.49K | 29.98K | 25.42K | 13.69K | 23.86K | 26.59K | 0.00 | 16.33K | 12.76K | 13.10K | 14.89M | 13.11K | 6.78K | 3.94K | 3.55K | 1.46K | -273.21K | 747.00 | 766.90 | 7.93K | -7.55K |
| EBITDA | -200.02M | -223.30M | -133.16M | -52.85M | -24.92M | -36.64M | -29.74M | -9.80M | -7.72M | -8.08M | -6.81M | -6.54M | -7.45M | -11.05M | -9.63M | -9.24M | -8.22M | -37.88M | -4.41M | 21.89M | -2.54M | -2.94M | -3.22M | -807.30K | -534.34K | 2.94B | 192.74K | 240.51K | -967.05K | -522.00K | -78.92K | -348.03K | -72.46K | -163.35K | -627.42K | -511.89K |
| EBITDA Ratio | -160,443.72% | -138,554.61% | -106,489.56% | -57,660.19% | -16,914.89% | -32,565.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -87,982.98% | -198,006.39% | 0.00% | 132,162.03% | -14,580.37% | 0.00% | -33,605.88% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | -36.67M | -29.91M | -9.90M | -8.08M | -7.00M | -6.29M | -7.25M | -8.95M | -11.23M | -10.17M | -7.57M | -12.66M | -37.90M | -3.92M | 17.61M | -1.81M | -2.97M | -3.25M | -833.02K | -547.44K | -741.67K | -1.23M | -1.06M | -970.99K | -525.55K | -80.38K | -74.82K | -73.21K | -164.12K | -635.35K | -504.34K |
| Operating Income Ratio | -153,885.37% | -138,647.99% | -106,575.99% | -57,815.66% | -16,929.71% | -32,595.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -88,191.87% | -198,139.25% | 0.00% | 131,983.17% | -14,797.71% | 0.00% | -33,943.71% | 0.00% | 0.00% | -0.03% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -37.81M | -70.67M | -3.41M | -14.23M | 310.76K | 1.03M | 2.98M | 535.06K | -16.02K | 2.24M | 1.16M | 958.26K | 1.72M | 855.19K | 1.17M | -1.70M | 7.18M | 24.55M | -661.28K | -1.01M | 5.87M | 495.02K | -1.92M | -8.17K | 1.28M | 2.32M | -771.54K | -1.04M | 81.90K | 53.27K | 35.07K | -266.53K | 12.70K | 25.31K | 142.78K | 93.62K |
| Income Before Tax | -229.65M | -220.69M | -136.68M | -67.41M | -24.39M | -35.55M | -28.92M | -9.36M | -8.10M | -6.23M | -6.45M | -5.99M | -7.48M | -11.80M | -5.81M | -7.97M | -1.07M | 10.19M | -4.58M | 16.60M | 4.06M | -2.45M | -3.23M | -828.22K | 730.42K | 1.58M | -1.23M | -1.06M | -889.09K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Income Before Tax Ratio | -184,215.67% | -136,936.62% | -109,300.18% | -73,285.73% | -16,716.71% | -31,598.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,445.89% | 53,289.60% | 0.00% | 124,394.23% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 0.05% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.41M | -8.81M | -8.69M | -6.62M | 8.27M | 14.64M | -12.02M | -3.17M | -1.57M | -2.09M | -2.69M | -1.42M | -2.46M | -831.43K | 93.06K | 37.02K | 1.12M | 4.85M | 252.37K | 2.79K | -5.87M | -83.76K | 85.58 | -39.80K | -1.28M | 2.37M | -1.98M | -1.40M | -1.13M | -665.00K | -62.00K | -511.00K | -81.00K | -181.00K | -621.00K | -544.00K |
| Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M | -20.91M | -16.90M | -6.19M | -6.51M | -4.07M | -3.76M | -4.34M | -4.95M | -10.97M | -5.91M | -8.00M | -1.10M | 9.50M | -4.80M | 16.60M | 4.06M | -2.36M | -3.23M | -801.17K | 730.42K | 1.58B | -1.23M | -1.05M | -857.59K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Net Income Ratio | -176,665.73% | -131,469.80% | -102,353.69% | -66,087.58% | -11,047.04% | -18,587.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,652.13% | 49,675.59% | 0.00% | 124,404.80% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 53.84% | -638.09% | -438.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 79.78M | 469.56M | 372.94M | 339.92M | 260.50M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 48.57M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
| Weighted Avg Shares Out (Dil) | 79.78M | 469.56M | 372.94M | 339.92M | 260.80M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 49.71M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1 ) will close at 5:00 pm (Melbourne time) on 10 July 2024 Prospectus and personalized...
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1 ) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
Financing extends Opthea's cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD
Opthea To Present at Clinical Trials at the Summit Meeting
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024...
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced...
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced...
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD),...
Source: https://incomestatements.info
Category: Stock Reports